Amphastar Pharmaceuticals Inc (Amphastar) is a bio-pharmaceutical company primarily engaged in the development, manufacturing, marketing, and sale of technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. The company manufactures and sells over 25 products, with a focus on prescription pharmaceuticals.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Amphastar focuses on various areas of research and development (R&D) activities such as pharmaceutical formulation, process development, toxicity studies, analytical, synthetic, and physical chemistry, drug delivery, device development, equipment and engineering, and clinical research statistical analysis, among others. Its spans pharmaceutical formulation, process development, toxicity studies, analytical, synthetic, and physical chemistry, drug delivery, device development, equipment and engineering, and clinical research statistical analysis. The company is currently working on building a portfolio of generic abbreviated new drug applications, proprietary product candidates, and biosimilar product candidates. As of December 31, 2024, the company had 322 employees in research and development activities. In FY2024, the company spent US$73.9 million on its R&D activities, which as a percentage of revenue stood at 10.1% and grew 0.2% YoY. Amphastar currently owns more than 100 issued patents globally. The company has several patent applications pending and owns several US and foreign patents covering processes and equipment used in the manufacture of a few products. The expiration dates of these patents range from 2025 to 2041. The company also owns several trademarks registered with the USPTO.